Indonesia and Russia are engaging in discussions to enhance their collaboration in pharmaceutical technology transfers, aiming to bolster domestic medicine production and reduce dependency on imports. The talks, involving Indonesia’s Food and Drug Authority (BPOM) and Russia’s Ministry of Industry and Trade, focus on improving medicine production and regulatory scrutiny.
The discussions, headed by BPOM’s Taruna Ikrar and Russian Deputy Minister Alexey Vladimirovich Gruzdev, covered various topics, including pharmaceutical manufacturing processes, quality control inspections, and digital technologies aimed at ensuring product safety and traceability. A significant focus was placed on increasing local production of diabetes treatments, such as insulin and glucagon-like peptide-1 (GLP-1) medicines, to enhance access to essential healthcare products.
Potential areas for cooperation extend to cancer treatments, monoclonal antibodies, antiviral medicines, and advanced biotechnology products. Russian companies showed interest in transferring technology and potentially setting up manufacturing facilities in Indonesia, with a particular focus on insulin, oncology medicines, and biotechnology products. Additionally, several Russian pharmaceutical companies have submitted product registration documents to BPOM.
The two countries also reviewed existing cooperation on Good Manufacturing Practice (GMP) inspections, technical training, and information sharing. They are working towards finalizing a memorandum of understanding to establish a robust framework for deeper collaboration. Part of the Russian proposal includes exploring mutual recognition of GMP certificates to ease regulatory procedures and facilitate market access for pharmaceuticals in both countries.
To further strengthen Indonesia’s inspection capabilities, Russia offered technical training, including virtual reality-based simulations, designed to prepare inspectors for pharmaceutical manufacturing assessments. Moreover, discussions encompassed digital regulatory systems and supply-chain monitoring, with both parties expressing interest in continuing negotiations and expanding cooperation through future meetings and visits to pharmaceutical manufacturing sites.